UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 83

Sortiert nach

A MATCHING‐ADJUSTED INDIRECT COMPARISON OF THE EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS ZANUBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

Hematological oncology, 2023-06, Vol.41 (S2), p.742-743

2023

Volltextzugriff (PDF)

Generating Health State Utility Values from Fact-Ovarian Data Collected in a Phase Ii Maintenance Study in Platinum Sensitive Recurrent Ovarian Cancer (Study 19): A Comparison of Mapping Algorithms

Value in health, 2014-11, Vol.17 (7), p.A646-A646

2014

Volltextzugriff (PDF)

CO172 Indirect Treatment Comparison of Efficacy and Safety of Capivasertib-Fulvestrant Versus Alpelisib-Fulvestrant for PIK3CA-Altered, HR-Positive, Advanced Breast Cancer after Disease Progression Following Endocrine-Based Therapy

Value in health, 2024-06, Vol.27 (6), p.S49-S50

2024

Volltextzugriff (PDF)

PT16 Impact of Data Maturity on the Estimation of the within-Trial Hazard Function: An Example from Metastatic Castration Resistant Prostate Cancer

Value in health, 2023-12, Vol.26 (12), p.S425-S426

2023

Volltextzugriff (PDF)

A MATCHING‐ADJUSTED INDIRECT COMPARISON OF THE EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS ZANUBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

Hematological oncology, 2023-06, Vol.41, p.742-743

2023

Volltextzugriff (PDF)

Cost Effectiveness of Bedaquiline for the Treatment of Multidrug-Resistant Tuberculosis

Value in health, 2014-11, Vol.17 (7), p.A595-A595

2014

Volltextzugriff (PDF)

Innovative Pricing and Reimbursement Schemes – The What, Why, Which, and How

Value in health, 2017-10, Vol.20 (9), p.A403-A404

2017

Volltextzugriff (PDF)

CP1 - Innovative Pricing and Reimbursement Schemes – The What, Why, Which, and How

Value in health, 2017-10, Vol.20 (9), p.A403-A404

2017

Volltextzugriff (PDF)

PCN96 A Systematic Review of Health State Utilities in Patients With Advanced Hepatocellular Carcinoma

Value in health, 2012-06, Vol.15 (4), p.A225-A225

2012

Volltextzugriff (PDF)

Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy

Annals of oncology, 2019-11, Vol.30, p.ix77-ix78

2019

Volltextzugriff (PDF)

HTA92 A Targeted Review of Methods for Effect Modifier (EM) and Prognostic Factor Identification in Population Adjusted Indirect Comparisons (PAICs) in NICE Oncology Submissions

Value in health, 2023-12, Vol.26 (12), p.S336

2023

Volltextzugriff (PDF)

PCV147 Framingham Risk Score in Health Economic Modelling: A European Perspective

Value in health, 2011, Vol.14 (7), p.A391-A391

2011

Volltextzugriff (PDF)

PIN49 A REVIEW OF EPIDEMIOLOGICAL LITERATURE ON THE BASIC REPRODUCTION NUMBER FOR THE 2009 NOVEL STRAIN OF H1N1

Value in health, 2011, Vol.14 (3), p.A122-A122

2011

Volltextzugriff (PDF)

PND7 Disability Progression in Patients with Relapsing Remitting Multiple Sclerosis (RRMS) Who Experience Disease Activity Despite Previous Disease Modifying Therapy

Value in health, 2011, Vol.14 (7), p.A318-A318

2011

Volltextzugriff (PDF)

EE317 Cost-Effectiveness of Adjuvant Olaparib in Germline BRCA1/2-Mutated, High-Risk, Human Epidermal Growth Factor-2-Negative Early Breast Cancer: A Canadian Perspective

Value in health, 2024-06, Vol.27 (6), p.S115-S116

2024

Volltextzugriff (PDF)

PCN72 Biomarker Testing to Guide Cost Effective Use of PARPi in Patients with Newly Diagnosed Ovarian Cancer

Value in health, 2020-12, Vol.23, p.S434-S434

2020

Volltextzugriff (PDF)

Survival Extrapolation Incorporating General Population Mortality Using Excess Hazard and Cure Models: A Tutorial

Medical decision making, 2023-08, Vol.43 (6), p.737-748

2023

Volltextzugriff (PDF)

84P Predicting longer-term progression-free survival (PFS) with durvalumab after chemoradiotherapy (CRT) in unresectable stage III NSCLC using a mixture cure model (MCM)

Annals of oncology, 2021-12, Vol.32, p.S1408-S1409

2021

Volltextzugriff (PDF)

Population adjusted indirect comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 studies of olaparib with or without bevacizumab, bev alone and placebo in the maintenance treatment of women with newly diagnosed stage III/IV ovarian cancer with BRCA mutation

Gynecologic oncology, 2020-10, Vol.159, p.19-20

2020

Volltextzugriff (PDF)

PND61 EVALUATION OF CONSISTENCY BETWEEN MULTIPLE SCLEROSIS REGISTRY PUBLICATIONS

Value in health, 2011, Vol.14 (3), p.A213-A213

2011

Volltextzugriff (PDF)

943P Association between event-free survival and overall survival following neoadjuvant therapy for non-small-cell lung cancer

Annals of oncology, 2022-09, Vol.33, p.S978

2022

Volltextzugriff (PDF)

Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore

Annals of oncology, 2019-11, Vol.30, p.ix79-ix80

2019

Volltextzugriff (PDF)

PSY75 - Cost-Effectiveness of Adding Novel or Group 5 Interventions To A Background Regimen For The Treatment of Multidrug-Resistant Tuberculosis In Germany

Value in health, 2016-11, Vol.19 (7), p.A588-A588

2016

Volltextzugriff (PDF)

Cost-Effectiveness of Adding Novel or Group 5 Interventions To A Background Regimen For The Treatment of Multidrug-Resistant Tuberculosis In Germany

Value in health, 2016-11, Vol.19 (7), p.A588-A588

2016

Volltextzugriff (PDF)

Achieving Optimal Fit-To-Survival Data Using Cubic Spline Models: A Case-Study Comparing The Fit of Standard and Cubic Spline Models to Survival Data from the Icon6 Study

Value in health, 2016-11, Vol.19 (7), p.A347-A347

2016

Volltextzugriff (PDF)

1 – 25 von 83

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(80)
Mit Volltextzugriff
(81)

Publikationsform

Sprache

Englisch
(83)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

A MATCHING‐ADJUSTED INDIRECT COMPARISON OF THE EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS ZANUBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

Generating Health State Utility Values from Fact-Ovarian Data Collected in a Phase Ii Maintenance Study in Platinum Sensitive Recurrent Ovarian Cancer (Study 19): A Comparison of Mapping Algorithms

CO172 Indirect Treatment Comparison of Efficacy and Safety of Capivasertib-Fulvestrant Versus Alpelisib-Fulvestrant for PIK3CA-Altered, HR-Positive, Advanced Breast Cancer after Disease Progression Following Endocrine-Based Therapy

PT16 Impact of Data Maturity on the Estimation of the within-Trial Hazard Function: An Example from Metastatic Castration Resistant Prostate Cancer

A MATCHING‐ADJUSTED INDIRECT COMPARISON OF THE EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS ZANUBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

Cost Effectiveness of Bedaquiline for the Treatment of Multidrug-Resistant Tuberculosis

Innovative Pricing and Reimbursement Schemes – The What, Why, Which, and How

CP1 - Innovative Pricing and Reimbursement Schemes – The What, Why, Which, and How

PCN96 A Systematic Review of Health State Utilities in Patients With Advanced Hepatocellular Carcinoma

Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy

HTA92 A Targeted Review of Methods for Effect Modifier (EM) and Prognostic Factor Identification in Population Adjusted Indirect Comparisons (PAICs) in NICE Oncology Submissions

PCV147 Framingham Risk Score in Health Economic Modelling: A European Perspective

PIN49 A REVIEW OF EPIDEMIOLOGICAL LITERATURE ON THE BASIC REPRODUCTION NUMBER FOR THE 2009 NOVEL STRAIN OF H1N1

PND7 Disability Progression in Patients with Relapsing Remitting Multiple Sclerosis (RRMS) Who Experience Disease Activity Despite Previous Disease Modifying Therapy

EE317 Cost-Effectiveness of Adjuvant Olaparib in Germline BRCA1/2-Mutated, High-Risk, Human Epidermal Growth Factor-2-Negative Early Breast Cancer: A Canadian Perspective

PCN72 Biomarker Testing to Guide Cost Effective Use of PARPi in Patients with Newly Diagnosed Ovarian Cancer

Survival Extrapolation Incorporating General Population Mortality Using Excess Hazard and Cure Models: A Tutorial

84P Predicting longer-term progression-free survival (PFS) with durvalumab after chemoradiotherapy (CRT) in unresectable stage III NSCLC using a mixture cure model (MCM)

Population adjusted indirect comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 studies of olaparib with or without bevacizumab, bev alone and placebo in the maintenance treatment of women with newly diagnosed stage III/IV ovarian cancer with BRCA mutation

PND61 EVALUATION OF CONSISTENCY BETWEEN MULTIPLE SCLEROSIS REGISTRY PUBLICATIONS

943P Association between event-free survival and overall survival following neoadjuvant therapy for non-small-cell lung cancer

Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore

PSY75 - Cost-Effectiveness of Adding Novel or Group 5 Interventions To A Background Regimen For The Treatment of Multidrug-Resistant Tuberculosis In Germany

Cost-Effectiveness of Adding Novel or Group 5 Interventions To A Background Regimen For The Treatment of Multidrug-Resistant Tuberculosis In Germany

Achieving Optimal Fit-To-Survival Data Using Cubic Spline Models: A Case-Study Comparing The Fit of Standard and Cubic Spline Models to Survival Data from the Icon6 Study

Suchergebnisse filtern